Zhaoke Ophthalmology announce that the company has recently established a partnership with the French pharmaceutical company FAREVA Group.
In May 2025, Zhaoke reached a memorandum of agreement (“MOA”) with FAREVA, a French contract manufacturing organization. According to the MOA, Zhaoke will become the recommended trusted partner for FAREVA’s customers who seek to manufacture pharmaceutical products in China.
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “At Zhaoke, our mission is to deliver high-quality ophthalmic treatments to patients worldwide. We are honoured that both our R&D and world-class manufacturing capabilities have been recognized by FAREVA, further validating our global standards. Developing drugs requires excellence at every stage – especially in R&D and manufacturing, where science becomes reality. Our state-of-the-art facility in Nansha, Guangzhou, China represents this commitment. Moreover, this strategic partnership also marks a significant step in our global expansion strategy. By joining forces with premier partners, we accelerate our ability to address unmet needs in eye care and expand access to cutting-edge therapies across key international markets.”